Therapy Areas: Autoimmune
Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
2 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation ...
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
25 February 2026 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Tuesday that it has submitted a supplemental Biologics License Application (sBLA) to the US Food ...
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
16 February 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Monday reported positive Phase III results from the MAJESTY study evaluating Gazyva (o...
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
16 February 2026 - Specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (SH:688177), a commercial-stage biopharmaceutical company, announced on Friday that they h...
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
12 February 2026 - Hong Kong-based biopharmaceutical company Akeso Inc (HK:9926) announced on Wednesday that it has received approval from China's National Medical Products Administration for the...